Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

Agricultural Bank Of China / Event-Driven

This is a new H/A Spread monitor project offering a brief look at recent changes in H-Share and A-Share spreads, Southbound flow and impact, and where the spreads are trading within their own historical ranges.
Main notes this week are:
<ul>
<li>HK$13.5bn of net buying by Southbound flows, which was 1.46% of HKEx Turnover - about in line with the previous four full weeks of trading. </li>
<li>Net buying since the last net selling day has been HK$48.8bn, which is not an unusual streak. </li>
<li>Southbound flows in the…</li>
</ul>

This is a new H/A Spread monitor project offering a brief look at recent changes in H-Share and A-Share spreads, Southbound flow and impact, and where the spreads are trading within their own historical ranges.
Main notes this week are:

HK$13.5bn of net buying by Southbound flows, which was 1.46% of HKEx Turnover - about in line with the previous four full weeks of trading. 
Net buying since the last net selling day has been HK$48.8bn, which is not an unusual streak. 
Southbound flows in the…


Quiddity Weekly H/A: Discounts & Southbound Flows 20180126

This is a new H/A Spread monitor project which attempts to give a brief look at recent changes in H-Share and A-Share spreads based on various influences and sector patterns. 
<h2>H-Share/A-Share Discounts, Changes over 1wk, 4wks and Changes in Southbound Flow</h2>
The first set of tables below show...
<ul>
<li class="">the discount of the major H-share listed companies to their respective A-share,</li>
<li class="">the change in discount over 1-week and 4-weeks (positive number means the H has outperformed the A),</li>
<li class="">a measure of decile…</li>
</ul>

This is a new H/A Spread monitor project which attempts to give a brief look at recent changes in H-Share and A-Share spreads based on various influences and sector patterns. 
H-Share/A-Share Discounts, Changes over 1wk, 4wks and Changes in Southbound Flow
The first set of tables below show...

the discount of the major H-share listed companies to their respective A-share,
the change in discount over 1-week and 4-weeks (positive number means the H has outperformed the A),
a measure of decile…


Quiddity Weekly H/A: Shares Discounts & Southbound Flows 20180112

Analyst

Alasdair Moody

Exposing Creative Accounting

Bucephalus Research Partnership

Bucephalus Research Partnership Limited. Exposing Creative Accounting.

At the Bucephalus Research Partnership (BRP) we analyse financial statements using our accountant's practical experience and our own quantitative algorithms for corporate governance, accounting risk and peer performance.

Our thematic research refines our unique algorithms while our single stock research focuses on examples where we discover a significant gap between published accounts and business reality.

​Bucephalus Research Partnership:
- Is an independent fee-based research service
- Does not take proprietary positions, long or short
- Does not solicit business or fees from the corporates we review

Thematic (Sector/Industry)

We examined ten years of accounting and valuation data for the pharmaceutical companies around the world with sales of US$100m+ and created statistics for each region based on aggregate data and for a typical company. In this trend report, we summarise the data and highlight the outliers. Assuming clients will have their own macro industry views, we used valuations and our Governance, Accounting risk and Peer performance (GAP) scores, (which help quantify the risk of creative accounting) to…

We examined ten years of accounting and valuation data for the pharmaceutical companies around the world with sales of US$100m+ and created statistics for each region based on aggregate data and for a typical company. In this trend report, we summarise the data and highlight the outliers. Assuming clients will have their own macro industry views, we used valuations and our Governance, Accounting risk and Peer performance (GAP) scores, (which help quantify the risk of creative accounting) to…

Global Pharmaceuticals: Valuations, Assets and Leverage Up - Margins Down

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

Sisram Medical is raising up to USD174m in its Hong Kong listing. Sisram Medical is an Israel headquartered meditech company with backing from China-based <a href="https://www.smartkarma.com/entities/8045" target="_blank" data-smartkarma-citation="entities:8045:1">Shanghai Fosun Pharmaceutical (Group) (2196 HK)</a>. In this insight, we will cover the company's background, its growth drivers, financial highlights, and score the deal in our ECM Framework.

Sisram Medical is raising up to USD174m in its Hong Kong listing. Sisram Medical is an Israel headquartered meditech company with backing from China-based Shanghai Fosun Pharmaceutical (Group) (2196 HK). In this insight, we will cover the company's background, its growth drivers, financial highlights, and score the deal in our ECM Framework. 

Sisram Medical IPO: Israeli Technology, China Story

Independent Insight Provider

Stewart Paterson

Macroeconomics

Any analysis of China's credit growth over the past six years or so would suggest that it is unsustainable and that as a result, when the day of reckoning comes, the country and the rest of the world will be hit by another deflationary shock. Indeed, global inflation has started to wane again in recent months (see: <a href="https://www.smartkarma.com/insights/money-matters-the-end-of-reflation" target="_blank" data-smartkarma-citation="insights:10500">Money Matters: The End of Reflation?</a>). Commodities have broadly speaking been weak and base effects mean headline numbers are fading. Investors however have broadly speaking pushed…

Any analysis of China's credit growth over the past six years or so would suggest that it is unsustainable and that as a result, when the day of reckoning comes, the country and the rest of the world will be hit by another deflationary shock. Indeed, global inflation has started to wane again in recent months (see: Money Matters: The End of Reflation?). Commodities have broadly speaking been weak and base effects mean headline numbers are fading. Investors however have broadly speaking pushed…

China

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a pharmaceutical company. Through its subsidiaries, the Company manufactures genetic medicines, Chinese traditional medicines, diagnostic products, and medical instruments, provides technology, marketing, and advertising services, as well as invests in import and export trading.

Shanghai Fosun Pharmaceutical (Group) (600196 CH)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Shanghai Fosun Pharmaceutical (Group) (600196 CH)

Quiddity Weekly H/A: Discounts & Southbound Flows 20180126

This is a new H/A Spread monitor project offering a brief look at recent changes in H-Share and A-Share spreads, Southbound flow and impact, and...

Travis Lundy

Quiddity Weekly H/A: Shares Discounts & Southbound Flows 20180112

This is a new H/A Spread monitor project which attempts to give a brief look at recent changes in H-Share and A-Share spreads based on various...

Travis Lundy

Global Pharmaceuticals: Valuations, Assets and Leverage Up - Margins Down

We examined ten years of accounting and valuation data for the pharmaceutical companies around the world with sales of US$100m+ and created...

Bucephalus Research Partnership

Sisram Medical IPO: Israeli Technology, China Story

Sisram Medical is raising up to USD174m in its Hong Kong listing. Sisram Medical is an Israel headquartered meditech company with backing from...

Ke Yan, CFA, FRM

Money Matters: A Fish Called Wanda

Any analysis of China's credit growth over the past six years or so would suggest that it is unsustainable and that as a result, when the day of...

Stewart Paterson

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)